Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Exelixis
Seagen Inc.
Bayer
Tizona Therapeutics, Inc
Washington University School of Medicine
Institute of Cancer Research, United Kingdom
City of Hope Medical Center
Emory University
Eli Lilly and Company
Dana-Farber Cancer Institute
Seagen Inc.
Novartis
University of Illinois at Chicago
Nanobiotix
Rondo Therapeutics
Hummingbird Bioscience
Massachusetts General Hospital
Valo Therapeutics Oy
Xencor, Inc.
Memorial Sloan Kettering Cancer Center
Sotio Biotech Inc.
Light Chain Bioscience - Novimmune SA
Adlai Nortye Biopharma Co., Ltd.
Columbia University
ADC Therapeutics S.A.
Pliant Therapeutics, Inc.
Eli Lilly and Company
Mayo Clinic
Hefei TG ImmunoPharma Co., Ltd.
Corvus Pharmaceuticals, Inc.
Oncorus, Inc.
Xencor, Inc.
Evelo Biosciences, Inc.
University of California, San Francisco
Eli Lilly and Company
Merck Sharp & Dohme LLC
Lytix Biopharma AS